Peterson Wealth Services Has $366,000 Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Peterson Wealth Services lifted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 19.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,860 shares of the medical research company’s stock after buying an additional 305 shares during the period. Peterson Wealth Services’ holdings in IQVIA were worth $366,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of IQV. FMR LLC lifted its holdings in shares of IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after acquiring an additional 804,963 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after purchasing an additional 583,396 shares during the last quarter. Impax Asset Management Group plc boosted its position in IQVIA by 9.7% in the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock valued at $423,885,000 after buying an additional 157,809 shares in the last quarter. Nordea Investment Management AB increased its holdings in shares of IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after buying an additional 452,029 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of IQVIA by 3.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,226,083 shares of the medical research company’s stock valued at $290,545,000 after acquiring an additional 39,772 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of recent research reports. Deutsche Bank Aktiengesellschaft lowered their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a report on Friday, November 1st. Leerink Partners reiterated an “outperform” rating and issued a $248.00 price objective (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. JPMorgan Chase & Co. reduced their target price on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $270.00 price target on shares of IQVIA in a research note on Monday. Finally, StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Five equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $252.50.

IQVIA Stock Performance

IQV opened at $206.67 on Tuesday. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73. The company has a market cap of $37.51 billion, a price-to-earnings ratio of 27.56, a PEG ratio of 2.25 and a beta of 1.48. The company’s fifty day moving average price is $200.67 and its two-hundred day moving average price is $219.27. The company has a current ratio of 0.84, a quick ratio of 0.81 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, analysts expect that IQVIA Holdings Inc. will post 10.81 EPS for the current fiscal year.

Insider Activity at IQVIA

In related news, Director John G. Danhakl acquired 1,275 shares of the company’s stock in a transaction on Tuesday, December 3rd. The shares were acquired at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the purchase, the director now owns 1,275 shares in the company, valued at approximately $255,739.50. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.60% of the stock is owned by insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.